TCGA-E9-A1NE-01A-21R-A14M-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 36
- os_event
- false
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088852 | — | — | 0.858 |
| 2 | SRR8518228 | — | D | 0.854 |
| 3 | TCGA-55-8089-01A-11R-2241-07 | — | cohortA1 | 0.850 |
| 4 | SRR8518454 | — | D | 0.843 |
| 5 | C3N-03765 | — | cohortA1 | 0.833 |
| 6 | SRR10900571 | — | — | 0.831 |
| 7 | MNG464 | — | — | 0.827 |
| 8 | BS_3MYEMXPQ | Med | Medulloblastoma | 0.824 |
| 9 | MNG215 | — | — | 0.822 |
| 10 | TCGA-69-7974-01A-11R-2187-07 | — | cohortA1 | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |